To investigate the potential involvement of the CSE-mediated mechanism in the effect of miR-27a on cardiac hypertrophy, we administered S-propargyl-cysteine (SPRC), a novel CSE modulator known to enhance myocardial ischemia protection through increased H2S expression, through intraperitoneal injection. The gene discussed is CTH; the disease is myocardial ischemia.